Online citations, reference lists, and bibliographies.
← Back to Search

Re-directed T Cells For The Treatment Of Fibroblast Activation Protein (FAP)-positive Malignant Pleural Mesothelioma (FAPME-1)

U. Petrausch, P. Schuberth, Christian Hagedorn, A. Soltermann, S. Tomaszek, R. Stahel, W. Weder, C. Renner
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BackgroundAsbestos is the main cause of MPM in industrialized countries. Even since asbestos is banned in most developed countries, the peak wave of MPM incidence is anticipated for the next years due to the long latency of asbestos induced MPM. MPM patients not eligible for surgical procedures like decortication or pleuro-pneumectomie have a median survival of 12 months with palliative chemotherapy. Therefore, new therapeutic approaches are of crucial need in this clinical situation.Methods/designThis is a phase I trial for patients with malignant pleural mesothelioma with pleural effusion testing the safety of a fixed single dose of 1x106 adoptively transferred FAP-specific re-directed T cells given directly in the pleural effusion. Lymphocytes will be taken 21 days before transfer from peripheral blood. CD8 positive T cells will be isolated and re-programmed by retroviral transfer of a chimeric antigen receptor recognizing FAP which serves as target structure in MPM. At day 0 of the protocol, re-directed T cells will be injected in the pleural effusion and patients will be monitored for 48h under intermediate care conditions. AE, SAE, SADR and SUSAR will be monitored for 35 days and evaluated by an independent safety board to define any dose limiting toxicity (DLT). No further patient can be treated before the previous patient passed day 14 after T cell transfer. The protocol will be judged as save when no DLT occurred in the first 3 patients, or 1 DLT in 6 patients. Secondary objectives are feasibility and immune monitoring.DiscussionAdoptive T cell transfer is a new and rapidly expanding branch of immunotherapies focusing on cancer treatment. Recently, objective responses could be observed in patients with chronic lymphatic leukemia treated with adoptively transferred CD19-specific re-directed T cells. The choice of the target antigen determines the possible on-target off-tissue toxicity of such approaches. There are reports of severe toxicity in patients who received T cells intravenously due to unexpected expression of the target antigen (on-target) in other tissues than the tumor (off-tissue). To minimize the risk of on-target off-tissue toxicity and to maximize the on-target anti-tumor effect we propose a clinical protocol with loco-regional administration of re-directed T cells. FAP-specific T cells will be directly injected in the pleural effusion of patients with MPM.Trial registrationClinicalTrials.gov (NCT01722149)
This paper references
10.1080/14653240601056396
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
C. Lamers (2006)
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
Petrausch (2012)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1200/JCO.1994.12.6.1193
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
S. Welt (1994)
10.1038/ncponc0666
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
P. Muranski (2006)
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
A. Scott (2003)
10.1510/icvts.2010.256271
Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
I. Zahid (2011)
10.1038/nri3191
Adoptive immunotherapy for cancer: harnessing the T cell response
N. Restifo (2012)
10.1038/nri2669
Antigen presentation in the thymus for positive selection and central tolerance induction
L. Klein (2009)
10.2486/INDHEALTH.45.379
Malignant mesothelioma: global incidence and relationship with asbestos.
C. Bianchi (2007)
10.1056/NEJMoa1103849
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
D. Porter (2011)
10.1053/j.semtcvs.2009.07.004
Multimodality strategies in malignant pleural mesothelioma.
W. Weder (2009)
10.1172/JCI22284
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
J. Pinthus (2004)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1038/mt.2010.24
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
R. Morgan (2010)
10.1073/pnas.0901425106
Rational development of high-affinity T-cell receptor-like antibodies
G. Stewart-Jones (2009)
10.1093/eurheartj/ehq519
Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata
Chad E. Brokopp (2011)
10.1007/s00262-004-0560-6
A listing of human tumor antigens recognized by T cells: March 2004 update
L. Novellino (2004)
10.1074/jbc.274.51.36505
Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts*
J. Park (1999)
10.1016/j.ejca.2009.04.028
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
J. Francart (2009)
8091 Zürich, Switzerland. 2 Department of Oncology
10.1016/S0140-6736(05)60646-0
UPDATE
angesichts der Corona-Pandemie (1998)
10.1158/0008-5472.CAN-10-4035
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.
H. Ertl (2011)
10.1016/J.EJCTS.2006.01.015
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
I. Opitz (2006)
10.1002/art.27395
Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.
C. Ospelt (2010)
10.1172/JCI32446
Adoptive T cell therapy for cancer in the clinic.
C. June (2007)
10.1016/j.ejcts.2009.08.016
Surgery for mesothelioma: MARS landing and future missions.
T. Treasure (2010)
10.1186/ar2080
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes
S. Bauer (2006)
10.1158/0008-5472.CAN-11-1396
Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010 (Cancer Research (2011) 71, (3175-3181))
H. Ertl (2011)
10.1182/blood-2010-07-294520
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
C. Lamers (2011)
10.1016/j.yexcr.2010.04.032
Activation of fibroblasts in cancer stroma.
K. Räsänen (2010)
10.1002/jgm.2604
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
K. Curran (2012)
10.1200/JCO.2006.05.9964
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
C. Lamers (2006)
10.1007/s002620000169
A listing of human tumor antigens recognized by T cells
N. Renkvist (2001)
10.1007/s10875-011-9532-8
Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice
Ana C. Parente-Pereira (2011)
10.1159/000069863
Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer
R. Hofheinz (2003)



This paper is referenced by
Neuartige bindemittel für anti-fibroblast-aktivierungsprotein (fap) und verwendungen davon
Benoît Combaluzier (2017)
10.3390/cancers9090115
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
Astero Klampatsa (2017)
10.1007/978-3-030-16884-1_19
Immunotherapy of Mesothelioma: Vaccines and Cell Therapy
Robert A. Belderbos (2019)
10.33696/immunology.2.042
Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
Astero Klampatsa (2020)
10.1111/imr.12139
Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells
M. Jensen (2014)
10.15252/emmm.201607485
Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
Jessica Hartmann (2017)
10.3390/vaccines4040041
Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment
A. Poggi (2016)
10.3109/08923973.2015.1100204
Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells
D. Alrifai (2016)
10.1080/14712598.2020.1819978
Emerging vistas in CAR T-cell therapy: Challenges and Opportunities in Solid Tumors.
Varada Date (2020)
10.1016/j.synbio.2018.08.001
Synthetic immunology: T-cell engineering and adoptive immunotherapy
W. Si (2018)
10.3892/mmr.2015.3197
Fibroblast activation protein α in tumor microenvironment: Recent progression and implications (Review)
F. Zi (2015)
10.1158/2326-6066.CIR-16-0011
Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
E. Puré (2016)
10.1186/s13045-018-0568-6
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
J. Li (2018)
10.1186/s13045-017-0444-9
Chimeric antigen receptor T cells: a novel therapy for solid tumors
S. Yu (2017)
10.1586/17476348.2015.1081066
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
10.12688/f1000research.10795.1
Harnessing the immune response to target tumors
L. Manning (2017)
10.1007/978-3-030-50287-4_31
Hurdles in Cancer Immunotherapy
F. Sadeghi (2021)
10.3389/fimmu.2018.00262
How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive
A. Poggi (2018)
10.1159/000477095
CARTs for Solid Tumors: Feasible or Infeasible?
W. Li (2017)
10.1146/annurev-pharmtox-010814-124844
Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
G. Gross (2016)
10.1158/1078-0432.CCR-17-1788
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
P. Gulati (2018)
10.3389/fimmu.2020.01109
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Alba Rodríguez-García (2020)
10.1016/j.tracli.2015.05.002
[New immunotherapeutic approaches in oncology and hematology].
Marie Kroemer (2015)
10.1080/2162402X.2018.1554969
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy (2019)
10.1016/J.TRACLI.2015.05.002
Nouvelles approches d’immunothérapie en onco-hématologie ☆
M. Kroemer (2015)
10.7150/ijbs.14405
New Strategies for the Treatment of Solid Tumors with CAR-T Cells
H. Zhang (2016)
10.1038/nrclinonc.2016.36
Driving CAR T-cells forward
H. Jackson (2016)
10.1016/j.trsl.2017.04.004
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
M. Zeltsman (2017)
10.1186/1479-5876-11-187
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
P. Schuberth (2013)
10.1016/j.bbapap.2020.140409
Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications.
A. Šimková (2020)
10.1016/j.annonc.2020.09.020
COVID-19-associated pancytopenia can be self-limiting and does not necessarily warrant bone marrow biopsy for the purposes of SARS-CoV-2 diagnostics
D.S. Hersby (2020)
10.1093/annonc/mdv101
Searching for targets for the systemic therapy of mesothelioma.
R. Stahel (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar